Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R A Boyd

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Cancer Research|December 15, 1992
Phase I and pharmacokinetic study of the novel platinum analogue CI-973 on a 5-daily dose scheduleP J O'Dwyer, G R Hudes, J Walczak, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 21, 2001
Il-4 therapy prevents the development of proteinuria in active Heymann nephritis by inhibition of Tc1 cellsS T Spicer, H Ha, R A Boyd, et al.
Clinical Pharmacology and Therapeutics|April 17, 2013
Model-based drug development: a rational approach to efficiently accelerate drug developmentP A Milligan, M J Brown, B Marchant, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Cancer Research|December 15, 1992
Phase I and pharmacokinetic study of the novel platinum analogue CI-973 on a 5-daily dose scheduleP J O'Dwyer, G R Hudes, J Walczak, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 21, 2001
Il-4 therapy prevents the development of proteinuria in active Heymann nephritis by inhibition of Tc1 cellsS T Spicer, H Ha, R A Boyd, et al.
Clinical Pharmacology and Therapeutics|April 17, 2013
Model-based drug development: a rational approach to efficiently accelerate drug developmentP A Milligan, M J Brown, B Marchant, et al.
Pageof 4